封面
市场调查报告书
商品编码
1629881

全球电生理学市场 - 2025-2033

Global Electrophysiology Market - 2025-2033

出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2023年,全球电生理学市场规模达82.4亿美元,预计2033年将达230亿美元,2025-2033年预测期间复合年增长率为10.7%。

电生理学是一个心臟病学领域,透过分析心臟的电活动来诊断和治疗异常心律。医疗保健提供者使用心导管和计算机从心臟内部创建心电图 (EKG) 追踪和电测量。这项研究有助于识别心跳讯号的问题,这些讯号通常遵循一致的路线。放置在心臟内的感测器比外部电极提供更多资讯。

市场动态:

驱动程式和限制

科技进步的崛起

由于诊断和治疗工具的技术进步,全球电生理学市场正在成长。先进的测绘系统、导管设计和机器人辅助程序正在提高心律不整的诊断和治疗效率。人工智慧和机器学习正在彻底改变资料分析,实现个人化治疗计划并降低手术风险。无线和小型化设备以及即时监测功能的发展正在扩大电生理学适应症,改善患者治疗效果并满足对微创手术日益增长的需求。

例如,2024 年 1 月,GE HealthCare 推出了带有 CardioLab EP 记录系统的 Prucka 3,这是一种尖端的电生理学工具,可帮助临床医生诊断和治疗心律不整。该系统建立在二十多年的电生理学专业知识之上,提供了全面的绘图技术生态系统,可在心律不整诊断和治疗中进行准确、高效和先进的分析。

缺乏熟练的专业人员

由于需要专业知识的程序复杂性,全球电生理学市场面临熟练专业人员的严重短缺。这,尤其是在发展中地区,可能会阻碍导管消融和电生理测绘系统等先进技术的广泛采用。这种短缺导致现有专业人员的压力增加、等待时间更长,并可能损害患者的治疗结果。解决此技能差距对于市场成长和先进技术的有效利用至关重要。

目录

第 1 章:方法与范围

第 2 章:定义与概述

第 3 章:执行摘要

第 4 章:动力学

  • 影响因素
    • 司机
      • 科技进步的崛起
    • 限制
      • 缺乏熟练的专业人员
    • 机会
    • 影响分析

第 5 章:产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析

第 6 章:依产品类型

  • EP消融导管
  • EP 诊断导管
  • EP实验室设备
  • 存取装置
  • 其他的

第 7 章:依指示

  • 心房颤动 (AF)
  • 心房扑动
  • 房室结折返性心搏过速 (AVNRT)
  • 室性心搏过速
  • 其他的

第 8 章:最终用户

  • 医院
  • 门诊手术中心 (ASC)
  • 专科诊所
  • 诊断中心

第 9 章:按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 10 章:竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章:公司简介

  • Biosense Webster, Inc. (Johnson & Johnson)
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Abbott Laboratories
  • Medtronic plc
  • Boston Scientific Corporation
  • Siemens Healthineers AG
  • GE HealthCare
  • Philips Healthcare
  • Acutus Medical, Inc.
  • Stereotaxis, Inc.
  • MicroPort Scientific Corporation

第 12 章:附录

简介目录
Product Code: MD8927

The global electrophysiology market reached US$ 8.24 billion in 2023 and is expected to reach US$ 23.0 billion by 2033, growing at a CAGR of 10.7% during the forecast period 2025-2033.

An electrophysiology is a cardiology field that analyzes the electrical activity in the heart to diagnose and treat abnormal heart rhythms. Healthcare providers use cardiac catheters and computers to create electrocardiogram (EKG) tracings and electrical measurements from inside the heart. The study helps identify issues with heartbeat signals, which typically follow a consistent route. The sensors placed inside the heart provide more information than external electrodes.

Market Dynamics: Drivers & Restraints

Rise in the Technological Advancements

The global electrophysiology market is growing due to technological advancements in diagnostic and therapeutic tools. Advanced mapping systems, catheter designs, and robotic-assisted procedures are improving cardiac arrhythmia diagnosis and treatment efficiency. Artificial intelligence and machine learning are revolutionizing data analysis, enabling personalized treatment plans and reducing procedural risks. The development of wireless and miniaturized devices and real-time monitoring capabilities is expanding electrophysiology Indications, improving patient outcomes and addressing the growing demand for minimally invasive procedures.

For instance, in January 2024, GE HealthCare has introduced the Prucka 3 with CardioLab EP Recording system, a cutting-edge electrophysiology tool, to aid clinicians in diagnosing and treating cardiac arrhythmias. This system, built on over twenty years of electrophysiology expertise, offers a comprehensive ecosystem of mapping technologies for accurate, efficient, and advanced analytics in cardiac arrhythmia diagnosis and treatment.

Shortage of Skilled Professionals

The global electrophysiology market faces a significant shortage of skilled professionals due to the complexity of procedures requiring specialized expertise. This, especially in developing regions, can hinder the widespread adoption of advanced technologies like catheter-based ablation and electrophysiology mapping systems. This shortage results in increased pressure on existing professionals, longer wait times, and potentially compromised patient outcomes. Addressing this skill gap is crucial for market growth and efficient use of advanced technologies.

Segment Analysis

The global electrophysiology market is segmented based on product type, indication, end user and region.

Product Type:

EP Ablation Catheters segment is expected to dominate the Electrophysiology market share

The EP ablation catheters segment holds a major portion of the electrophysiology market share and is expected to continue to hold a significant portion of the electrophysiology market share during the forecast period.

EP ablation catheters are essential in the global electrophysiology market for treating arrhythmias like atrial fibrillation and ventricular tachycardia. They deliver radiofrequency energy or cryotherapy to specific heart areas, disrupting abnormal electrical pathways. Their growth is driven by the rise in cardiovascular diseases, advancements in catheter technology, and the need for more efficient, safer, and less invasive treatments. Innovations like improved designs, navigation systems, and real-time imaging have made EP ablation catheters a cornerstone in electrophysiology, improving patient outcomes and market expansion.

For instance, in October 2024, Medtronic has received FDA approval for an early feasibility study to evaluate the Affera Mapping and Ablation System with Sphere-9 Catheter for treating sustained ventricular tachycardia (VT), a potentially life-threatening abnormal heart rhythm affecting the lower chamber of the heart. The system is an all-in-one, dual-energy ablation and high-density mapping catheter used in cardiac electrophysiology ablation procedures.

Indication:

Atrial Fibrillation (AF) segment is the fastest-growing segment in Electrophysiology market share

The atrial fibrillation (AF) segment is the fastest-growing segment in the electrophysiology market share and is expected to hold the market share over the forecast period.

Atrial fibrillation (AF) is a rapidly growing cardiovascular condition that demands precise diagnosis and management through electrophysiology procedures like catheter ablation. The increasing prevalence of AF due to aging populations and risk factors like hypertension and diabetes has driven demand for advanced electrophysiology technologies and treatments. The market growth is accelerated by the need for innovative diagnostic tools, ablation catheters, and advanced mapping systems. Improved treatment options like cryoablation and radiofrequency ablation are providing better outcomes for AF patients, making it a central focus within the electrophysiology sector.

For instance, in November 2024, Johnson & Johnson MedTech has received FDA approval for the VARIPULSE Platform, a device designed to treat drug refractory paroxysmal Atrial Fibrillation (AFib). The VARIPULSE Platform combines PFA therapy and advanced mapping with the CARTO 3 System, a leading 3D electroanatomical cardiac mapping system. It is designed for full integration with CARTO.

Geographical Analysis

North America is expected to hold a significant position in the Electrophysiology market share

North America holds a substantial position in the electrophysiology market and is expected to hold most of the market share due to advanced healthcare infrastructure, acquisitions, high healthcare spending, and emphasis on technological innovations. The region's medical device industry invests heavily in research and development for cutting-edge electrophysiology technologies. The increasing prevalence of cardiovascular diseases and aging population drive demand for electrophysiology procedures. North America's skilled healthcare professionals and favourable reimbursement policies further fuel the market's growth.

For instance, in November 2024, Boston Scientific has acquired Cortex, a pioneer in pulsed field ablation (PFA) technology, to enhance its capabilities in electrophysiology and cardiac care solutions. This acquisition is a significant step for Boston Scientific, which aims to refine treatments for heart rhythm disorders, potentially improving patient outcomes.

Moreover, in May 2024, Biosense Webster, part of Johnson & Johnson MedTech, has launched CARTO 3 System Version 8, the latest version of its three-dimensional heart mapping system for cardiac ablation procedures. The software includes new modules like the CARTO ELEVATE Module and CARTOSOUND FAM Module, enhancing efficiency, reproducibility, and accuracy for electrophysiologists treating patients with atrial fibrillation and other arrhythmias.

Europe is growing at the fastest pace in the Electrophysiology market

Europe holds the fastest pace in the electrophysiology market and is expected to hold most of the market share due to ageing population and increasing heart disease incidence. The demand for minimally invasive procedures is increasing due to their effectiveness in treating arrhythmias and other heart conditions. Advanced diagnostic technologies, like catheter-based ablation and mapping systems, are gaining popularity in advanced countries like Germany, France, and the UK. Collaboration between healthcare providers and manufacturers, regulatory support, and a focus on personalized medicine contribute to the market's growth.

For instance, in July 2024, Volta Medical has announced a Joint Development Agreement with GE HealthCare to integrate its Volta AF-Xplorer AI solution with GE HealthCare's Prucka 3 and CardioLab EP Recording system. The goal is to improve performance and streamline workflows for electrophysiologists during catheter ablation procedures for treating atrial fibrillation (AFib), enhancing their efficiency.

Competitive Landscape

The major global players in the Electrophysiology market include Biosense Webster, Inc. (Johnson & Johnson), Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Siemens Healthineers AG, GE HealthCare, Philips Healthcare, Acutus Medical, Inc, Stereotaxis, Inc, MicroPort Scientific Corporation and among others.

Key Developments

  • In December 2024, Havasu Regional Medical Center, a LifePoint hospital, has launched an electrophysiology program to diagnose and treat heart arrhythmia. The program aims to improve patient outcomes and reduce the stress and financial burden associated with traveling for care. Arrhythmias, which occur when the heart beats too slowly, too fast, or irregularly, affect around 9.5 million people in the US. AFib, the most common type, has a five-fold higher stroke risk in those with AFib compared to those without it.
  • In October 2024, KIMSHEALTH Trivandrum has inaugurated a state-of-the-art Electrophysiology Lab with advanced 3D mapping technology, inaugurated by Dr. S Somanath, Chairman of ISRO.

Emerging Players

The emerging players in the electrophysiology market include CathRx, Grid Medical, Acutus Medical, CardioFocus, Inc and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global electrophysiology market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Technological Advancements
    • 4.1.2. Restraints
      • 4.1.2.1. Shortage of Skilled Professionals
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. EP Ablation Catheters *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. EP Diagnostic Catheters
  • 6.4. EP Laboratory Devices
  • 6.5. Access Devices
  • 6.6. Others

7. By Indication

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 7.1.2. Market Attractiveness Index, By Indication
  • 7.2. Atrial Fibrillation (AF)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Atrial Flutter
  • 7.4. Atrioventricular Nodal Reentry Tachycardia (AVNRT)
  • 7.5. Ventricular Tachycardia
  • 7.6. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Ambulatory Surgical Centers (ASCs)
  • 8.4. Specialized Clinics
  • 8.5. Diagnostic Centers

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Biosense Webster, Inc. (Johnson & Johnson)*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Abbott Laboratories
  • 11.3. Medtronic plc
  • 11.4. Boston Scientific Corporation
  • 11.5. Siemens Healthineers AG
  • 11.6. GE HealthCare
  • 11.7. Philips Healthcare
  • 11.8. Acutus Medical, Inc.
  • 11.9. Stereotaxis, Inc.
  • 11.10. MicroPort Scientific Corporation

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us